IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC.
2:15-cv-06934
Overview
Parties
Defendant
ACTAVIS PHARMA INC. Operating Company
Represented By
4 Attorneys ListedWALSH PIZZI O'REILLY FALANGA LLP
ONE RIVERFRONT PLAZA, 1037 RAYMOND BLVD.
WALSH PIZZI O'REILLY FALANGA LLP
ONE RIVERFRONT PLAZA, 1037 RAYMOND BLVD., 6TH FLOOR
WALSH PIZZI O'REILLY FALANGA LLP
ONE RIVERFRONT PLAZA, 1037 RAYMOND BLVD.
ACTAVIS LABORATORIES FL, INC. Operating Company
Represented By
4 Attorneys ListedWALSH PIZZI O'REILLY FALANGA LLP
ONE RIVERFRONT PLAZA, 1037 RAYMOND BLVD.
WALSH PIZZI O'REILLY FALANGA LLP
ONE RIVERFRONT PLAZA, 1037 RAYMOND BLVD., 6TH FLOOR
WALSH PIZZI O'REILLY FALANGA LLP
ONE RIVERFRONT PLAZA, 1037 RAYMOND BLVD.
Plaintiff
Court & Judges
Court
District Court, D. New Jersey (njd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 13 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 7,094,427 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| π―π΅ Japan | JP 2004508790 A | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 2005528430 A | Japan Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 3,756,204 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 1,507,518 B1 | European Counterpart (EP) | View Official Patent → |
| π¨π¦ Canada | CA 002486859 A | Canada Counterpart | View Official Patent → |
| π¨π¦ Canada | CA 2486859 C | Canada Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 15,000,435 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 2,921,170 A1 | European Counterpart (EP) | View Official Patent → |
| π PCT International (WIPO) | WO 2003101432 A1 | PCT World Application | View Official Patent → |
| πΊπΈ United States | US 2005014767 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2006001387 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2003022404 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7094427
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
Filed: 2002-09-12
Issued: 2006-08-22
|
Expired (Term Ended)
Expires: 2022-09-12
|
|
|
US8377474
Controlled release formulations of levodopa and uses thereof
|
Filed: 2008-12-26
Issued: 2013-02-19
|
Active (2.1 yrs remaining)
Expires: 2028-12-26
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
48
Dispositive
24
Granted
10
Denied
0
Pending / Review
19
Motions by Category
Key Dispositive Motions & Rulings